Are Placebos a Form of Deception?

If participants receive a placebo without knowing which treatment they received, are they being deceived?

Placebo-controlled studies can look deceptive at first glance. Participants may swallow a pill, receive an injection, or undergo another procedure without knowing whether it contains the intervention being tested. Researchers may know the assignment, or in a double-blind study they may not know either.

Yet uncertainty about treatment assignment is not necessarily the same as deception. A participant can knowingly agree to randomization and understand that one possible assignment is a placebo while remaining blinded to which condition they actually receive.

The ethical distinction depends on what participants were told before enrollment, what they agreed to, and whether researchers intentionally created a false understanding rather than merely preserving an agreed-upon blind.

A placebo is not inherently deceptive

Placebo, blinding, and deception are different concepts

A placebo is a control intervention, not a statement to the participant

A placebo is generally an intervention designed to resemble the intervention under investigation while lacking the specific component or action being tested. Placebo controls can help researchers distinguish effects attributable to the intervention from changes associated with expectations, natural variation, regression toward the mean, attention, and other influences.

Whether this involves deception depends on the informational relationship between researchers and participants. The placebo itself does not tell a lie. Researchers can use it within a consent process that openly explains the possibility of placebo assignment.

Blinding means withholding assignment, not necessarily misleading participants

In a blinded randomized trial, participants may know from the beginning that they could receive either the experimental intervention or a placebo. What they do not know is their individual assignment.

That uncertainty can be part of what they knowingly agreed to. The U.S. Common Rule's definition of a clinical trial expressly recognizes that prospectively assigned interventions may include placebo or another control. HHS informed-consent requirements, meanwhile, call for participants to receive information about the research purpose, procedures, reasonably foreseeable risks and discomforts, expected benefits, and appropriate alternatives where applicable.

The first preserves uncertainty that the participant has agreed to. The second affirmatively creates a false belief.

Informed uncertainty is not the same as deception

Informed consent does not require participants to know every future event with certainty. Randomization itself means researchers cannot promise which study arm a participant will enter. Blinding means some information is deliberately unavailable during the study.

What matters is whether participants understand the relevant uncertainty. Someone who knowingly agrees to a 50% possibility of receiving placebo is in a different ethical position from someone who believes with certainty that an active treatment is being provided because researchers told them so.

This illustrates the broader distinction between deception and incomplete disclosure. Not knowing something does not automatically mean someone has been deceived.

Placebo use and placebo deception are separate ethical questions

Even when placebo assignment is fully disclosed, researchers still need to justify whether a placebo control is ethically appropriate.

The 2024 Declaration of Helsinki states that new interventions should ordinarily be tested against the best proven intervention. It permits placebo or no intervention when no proven intervention exists. When a proven intervention does exist, placebo, no intervention, or an intervention less effective than the best proven intervention may be used for compelling and scientifically sound methodological reasons when necessary to determine efficacy or safety, provided participants will not face additional risks of serious or irreversible harm from not receiving the best proven intervention.

These restrictions concern whether it is ethically acceptable to assign someone to placebo, particularly when an effective intervention already exists. That issue should not be confused with whether participants were deceived about the assignment.

A placebo can be used without concealing that placebos exist

Researchers sometimes assume that a placebo works scientifically only if participants believe they are definitely receiving an active intervention. That is not how conventional blinded placebo-controlled trials need to operate.

Participants can be told that placebo assignment is possible while remaining uncertain about their own assignment. The blind can therefore be maintained without falsely promising active treatment.

That distinction is particularly important in clinical research, where misunderstanding about whether participation guarantees treatment can interfere with meaningful consent.

Open-label placebos make the distinction even clearer

Some research investigates open-label placebos, in which participants are explicitly told that the intervention is a placebo. Such studies demonstrate at a conceptual level that placebo administration and deception are not inseparable.

Whether an open-label placebo produces a clinically meaningful effect in a particular condition is an empirical question, and findings vary by context. But from an ethics perspective, openly identifying an intervention as placebo removes the false-belief component that characterizes deceptive administration.

A placebo can become part of a deceptive design

Now consider a different study. Participants are told, “Everyone in this study receives the active intervention,” but some participants actually receive placebo. If researchers know that statement is false, the study involves active deception about treatment assignment.

Alternatively, researchers might deliberately conceal the existence of a placebo arm when applicable consent requirements call for that information. That creates an informed-consent problem even if researchers avoid an explicit false statement.

The ethical analysis then extends beyond ordinary blinding to the broader conditions governing deception in research.

Deception cannot be used casually to strengthen expectancy effects

A researcher might reason that telling participants they are definitely receiving treatment would strengthen expectations and therefore make the placebo manipulation more powerful. Scientifically, that could be useful for some research questions. Ethically, usefulness alone is insufficient.

For psychologists governed by APA Standard 8.07, deception requires significant prospective scientific, educational, or applied value and the absence of feasible effective nondeceptive alternatives. Researchers also may not deceive prospective participants about research reasonably expected to cause physical pain or severe emotional distress, and integral deception must be explained as early as feasible under the standard.

The familiar label “placebo” therefore does not create a special exemption from ordinary rules governing deception.

The same placebo can be administered with or without deception

Whether the placebo-controlled trial is otherwise ethical still depends on the clinical context, available proven interventions, risks, scientific justification, consent, and applicable review requirements. The example isolates only the question of deception.

Common misconceptions about placebos and deception

Separate the blind from the information participants are entitled to receive

If your study uses placebo, do not ask only whether participants know their assignment. Ask what they were told about the possible assignments before agreeing to participate.

A scientifically useful blind can often be maintained while being transparent about the existence of placebo. If your design instead requires participants to believe something researchers know is false, you have moved from ordinary blinding into deception and should justify it accordingly.

Finally, do not let the word “placebo” obscure the actual procedure. Describe exactly what participants will be told, what they may receive, what remains blinded, and whether any statement about treatment assignment is intentionally false.

Before using a placebo, separate blinding from deception

Frequently asked questions about placebos and deception

A placebo can preserve uncertainty without creating a false belief

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.